85 related articles for article (PubMed ID: 9360780)
1. Peptide analogs that inhibit IgE-Fc epsilon RI alpha interactions ameliorate the development of lethal graft-versus-host disease.
Korngold R; Jameson BA; McDonnell JM; Leighton C; Sutton BJ; Gould HJ; Murphy GF
Biol Blood Marrow Transplant; 1997 Oct; 3(4):187-93. PubMed ID: 9360780
[TBL] [Abstract][Full Text] [Related]
2. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
3. Human IgE receptor alpha-chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo.
Haak-Frendscho M; Ridgway J; Shields R; Robbins K; Gorman C; Jardieu P
J Immunol; 1993 Jul; 151(1):351-8. PubMed ID: 7686940
[TBL] [Abstract][Full Text] [Related]
4. Amino acid residues that influence Fc epsilon RI-mediated effector functions of human immunoglobulin E.
Sayers I; Cain SA; Swan JR; Pickett MA; Watt PJ; Holgate ST; Padlan EA; Schuck P; Helm BA
Biochemistry; 1998 Nov; 37(46):16152-64. PubMed ID: 9819207
[TBL] [Abstract][Full Text] [Related]
5. Thermodynamics of the interaction of human immunoglobulin E with its high-affinity receptor Fc epsilon RI.
Keown MB; Henry AJ; Ghirlando R; Sutton BJ; Gould HJ
Biochemistry; 1998 Jun; 37(25):8863-9. PubMed ID: 9636027
[TBL] [Abstract][Full Text] [Related]
6. Affinity improvement of the high-affinity immunoglobulin E receptor by phage display.
Iwasaki A; Doi T; Umetani M; Watanabe M; Suda M; Hattori Y; Nagoya T
Biochem Biophys Res Commun; 2002 Apr; 293(1):542-8. PubMed ID: 12054635
[TBL] [Abstract][Full Text] [Related]
7. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation.
Maurer D; Fiebiger E; Reininger B; Ebner C; Petzelbauer P; Shi GP; Chapman HA; Stingl G
J Immunol; 1998 Sep; 161(6):2731-9. PubMed ID: 9743330
[TBL] [Abstract][Full Text] [Related]
8. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
Jones SC; Friedman TM; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
[TBL] [Abstract][Full Text] [Related]
9. [Ala12]MCD peptide: a lead peptide to inhibitors of immunoglobulin E binding to mast cell receptors.
Buku A; Condie BA; Price JA; Mezei M
J Pept Res; 2005 Sep; 66(3):132-7. PubMed ID: 16083440
[TBL] [Abstract][Full Text] [Related]
10. Expression of recombinant soluble Fc epsilon RI: function and tissue distribution studies.
Gavin AL; Snider J; Hulett MD; Mckenzie IF; Hogarth PM
Immunology; 1995 Nov; 86(3):392-8. PubMed ID: 8550076
[TBL] [Abstract][Full Text] [Related]
11. Generation of canine-human Fc IgE chimeric antibodies for the determination of the canine IgE domain of interaction with Fc epsilon RI alpha.
Hunter MJ; Vratimos AP; Housden JE; Helm BA
Mol Immunol; 2008 Apr; 45(8):2262-8. PubMed ID: 18187193
[TBL] [Abstract][Full Text] [Related]
12. Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells.
Luiten RM; Warnaar SO; Schuurman J; Pasmans SG; Latour S; Daëron M; Fleuren GJ; Litvinov SV
Hum Antibodies; 1997; 8(4):169-80. PubMed ID: 9395919
[TBL] [Abstract][Full Text] [Related]
13. Fc(epsilon)RI and FcgammaRIII/CD16 differentially regulate atopic dermatitis in mice.
Abboud G; Staumont-Sallé D; Kanda A; Roumier T; Deruytter N; Lavogiez C; Fleury S; Rémy P; Papin JP; Capron M; Dombrowicz D
J Immunol; 2009 May; 182(10):6517-26. PubMed ID: 19414806
[TBL] [Abstract][Full Text] [Related]
14. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
15. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
16. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
17. Relative importance of CD4+ and CD8+ T cell repertoires in the development of acute graft-versus-host disease in a murine model of bone marrow transplantation.
Miconnet I; de La Selle V; Bruley-Rosset M
Bone Marrow Transplant; 1998 Mar; 21(6):583-90. PubMed ID: 9543062
[TBL] [Abstract][Full Text] [Related]
18. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C
Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783
[TBL] [Abstract][Full Text] [Related]
19. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation.
Hattori K; Hirano T; Miyajima H; Yamakawa N; Ikeda S; Yoshino K; Tateno M; Oshimi K; Kayagaki N; Yagita H; Okumura K
Br J Haematol; 1999 Apr; 105(1):303-12. PubMed ID: 10233398
[TBL] [Abstract][Full Text] [Related]
20. Antitumor IgE adjuvanticity: key role of Fc epsilon RI.
Nigro EA; Brini AT; Soprana E; Ambrosi A; Dombrowicz D; Siccardi AG; Vangelista L
J Immunol; 2009 Oct; 183(7):4530-6. PubMed ID: 19748979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
